Stock · Healthcare
LLY Eli Lilly and Company
Eli Lilly and Company scores well across yield, structure, and size — a typical strong-safety profile.
Why we rate it 8.8
- Low yield of 0.62% — typical of growth-tilted stocks
- Payout ratio of 22% leaves significant room to grow the dividend or absorb earnings dips
- Current yield is below the 5-year average (0.89%), often a sign that price has appreciated faster than dividend growth
- Mega-cap scale (>$200B) — market dominance reduces dividend pressure
Where LLY ranks
We compute the same 0–10 safety score across 53 dividend-paying stocks and ETFs. Here's where LLY lands inside that universe.
The universe is curated to the most-searched US dividend payers. We'll expand it as the data layer grows; sector percentiles only appear when we have at least 5 comparable peers.
The two questions a safety score doesn't answer
A safety score tells you how durable LLY's payout looks. It does not tell you what you keep after tax, or whether something else does the same job better.
On tax: what you actually pocket depends on whether LLY dividends are qualified — qualified distributions are taxed at 0%, 15%, or 20%, while ordinary ones are taxed at your full marginal rate, a gap that can reach 22 percentage points of the income on the same headline yield.
On substitutes: if LLY's 8.8/10 score is lower than you want, see LLY alternatives — same-sector stocks ranked by how closely they match LLY on both yield and safety, so you can see what a swap actually costs you.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
How we score dividend safety
The Infnits dividend safety score is a 0–10 rating derived from yield zone, payout ratio (when applicable), yield trend versus 5-year average, instrument type, and company size. Each factor is independently transparent — see the reasons above for exactly which factors contributed to LLY's score.
For the full methodology including the in-app version that uses ETF look-through and historical cut data, see our methodology page.
This is educational, not investment advice. Dividend safety scores reflect a snapshot of public data on the "as of" date shown. Verify current data on the issuer's investor relations page or your brokerage before making decisions.
Frequently asked questions
Is LLY safe?
On dividend safety specifically, Infnits scores LLY 8.8/10 — strong. Eli Lilly and Company scores well across yield, structure, and size — a typical strong-safety profile. That score measures how durable the payout looks based on yield zone, payout ratio, yield trend, and instrument type; it does not measure price risk, valuation, or whether LLY suits your portfolio.
Is LLY's dividend safe?
Based on snapshot data — yield 0.62%, payout ratio 22%, instrument type stock — Infnits rates LLY's dividend safety profile as strong (8.8/10). This is one signal, not a recommendation.
What is LLY's current dividend yield?
LLY has a current dividend yield of 0.62% as of September 10, 2026. Its 5-year average yield is 0.89%.
How is LLY's safety score calculated?
The score combines yield zone (yields above 7% historically carry elevated cut risk), payout ratio (lower is safer), trend vs. 5-year average yield, instrument type (ETFs are inherently more diversified), and size (larger companies have more stable cash flows). Each factor is scored 0-2.5 and summed to a 0-10 result.
Where does this data come from?
Fundamentals are sourced from public market data and refreshed regularly. The "as of" date on each page reflects the snapshot used for the score. For real-time data, check the issuer's investor relations page or your brokerage.
Should I buy LLY based on this score?
No — this is an educational score based on a handful of public signals, not investment advice. Use it as one input among many. For a portfolio-aware analysis with ETF look-through and personalized insights, install the Infnits app.
Get emailed when LLY score changes.
LLY head-to-head comparisons
See LLY compared side-by-side with the most-searched peer tickers — yield, safety, growth trend, expense ratio, and tax treatment.
More LLY analysis
Other dividend tickers
See how LLY fits your portfolio
Add your other holdings and the free analyzer shows your total annual income, weighted safety score, and whether LLY is carrying too much of your income. Runs in your browser — no account, no download.
Or read how safety scoring works.